New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Core Viewpoint - Invivyd, Inc. has published a peer-reviewed analysis demonstrating that clinical protection levels from COVID can be predicted based on laboratory-determined serum monoclonal antibody activity levels, regardless of virus variation, supporting the use of monoclonal antibodies in clinical decision-making and public health stewardship [1][2][3] Group 1: Clinical Trial Insights - The CANOPY Phase 3 clinical trial assessed the clinical protection of Invivyd's monoclonal antibody pemivibart in reducing symptomatic COVID, establishing a statistically derived correlate of protection curve that illustrates the relationship between antibody activity and protection from symptomatic disease [2][3][4] - The analysis indicates that clinical efficacy can be predicted from stable epitopes of monoclonal antibodies, showing meaningful protection even at low antibody levels, which aligns with normal human immune physiology [2][3][5] Group 2: Implications for Healthcare - The findings from the peer-reviewed analysis could accelerate regulatory pathways for monoclonal antibodies, potentially reducing the need for animal models or extensive trials, and expanding COVID-19 protection strategies beyond annual vaccine boosting [2][3][6] - The model provides a mechanism for healthcare professionals and regulators to quantify the relationship between monoclonal antibodies and clinical protection, facilitating better understanding and application in public health [6][2] Group 3: Product Information - PEMGARDA (pemivibart) is an investigational monoclonal antibody with a robust safety profile, demonstrating in vitro neutralizing activity against major SARS-CoV-2 variants and targeting the spike protein receptor binding domain to inhibit virus attachment [7][8] - The emergency use authorization (EUA) for PEMGARDA is specifically for pre-exposure prophylaxis in adults and adolescents with moderate-to-severe immune compromise, and it is not a substitute for vaccination [8][9]